Cibus' (CBUS) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Cibus' stock has been reaffirmed with a "sell (e+)" rating by Weiss Ratings, indicating ongoing concerns about its performance.
• The company reported a negative earnings per share (EPS) of ($0.61) for the last quarter, exceeding analysts' expectations but still indicating financial struggles.
• Institutional investors currently hold 33.81% of Cibus' stock, with several hedge funds recently acquiring new stakes in the company.

Cibus (NASDAQ:CBUS - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Cibus Stock Performance

NASDAQ CBUS traded up $0.04 during trading hours on Wednesday, reaching $1.47. The company's stock had a trading volume of 88,803 shares, compared to its average volume of 198,524. The business has a 50-day simple moving average of $1.38 and a 200 day simple moving average of $1.74. Cibus has a 52 week low of $1.20 and a 52 week high of $6.10.

Cibus (NASDAQ:CBUS - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.08. Cibus had a negative net margin of 5,681.55% and a negative return on equity of 83.67%. The firm had revenue of $0.93 million for the quarter, compared to analysts' expectations of $1.15 million. As a group, sell-side analysts forecast that Cibus will post -2.96 earnings per share for the current year.

Institutional Investors Weigh In On Cibus

A number of hedge funds have recently made changes to their positions in CBUS. Blair William & Co. IL bought a new stake in shares of Cibus during the first quarter valued at approximately $28,000. Qube Research & Technologies Ltd bought a new stake in shares of Cibus during the second quarter valued at approximately $39,000. Warberg Asset Management LLC bought a new stake in shares of Cibus during the second quarter valued at approximately $41,000. FNY Investment Advisers LLC bought a new stake in shares of Cibus during the second quarter valued at approximately $54,000. Finally, Two Sigma Investments LP bought a new stake in shares of Cibus during the fourth quarter valued at approximately $68,000. Institutional investors own 33.81% of the company's stock.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.